GILD

$170.390.17%-0.29

Nachbörslich: 170.86+0.47 +0.28%

Gilead Sciences Inc (GILD)

Date: O: H: L: C: Vol:

Schlusskurs vom Vortag:

$170.68

Offen:

$169.85

24-Stunden-Volumen:

6,565,015

Relatives Volumen:

0.96

Marktkapitalisierung:

$211.34B

Einnahmen:

$29.79B

Nettoeinkommen (Verlust:

$9.22B

KGV:

23.18

EPS:

$7.35

Netto-Cashflow:

$10.23B

1W Leistung:

+7.37%

1M Leistung:

+17.72%

6M Leistung:

+29.43%

1Y Leistung:

+42.24%

1-Tages-Spanne:

$166.38$172.61

1-Wochen-Bereich:

$156.04$175.65

52-Wochen-Spanne:

$114.02$175.65

Gilead Sciences Inc Aktie (GILD) Unternehmensprofil

Firmenname

Gilead Sciences Inc

Sektor

Healthcare

Branche

Drug Manufacturers - General

Telefon

(650) 574-3000

Adresse

333 LAKESIDE DR, FOSTER CITY, CA, USA

Mitarbeiter

17,000

@GileadSciences

Nächster Verdiensttermin

null

Neueste SEC-Einreichungen

SEC

GILD-Diskussionen auf X

GILD vs. LLY, JNJ, ABBV, MRK, NVS vergleichen

Aktien	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
GILD Gilead Sciences Inc	$211.34B	$30.99B	-$3.86B	$13.78B	$7.35
LLY Lilly Eli Co	$1.26T	$86.46B	$27.58B	$10.37B	$27.78
JNJ Johnson Johnson	$651.30B	$99.34B	$16.10B	$20.59B	$8.63
ABBV Abbvie Inc	$510.48B	$64.39B	$6.31B	$18.21B	$2.03
MRK Merck Co Inc	$366.35B	$66.57B	$3.17B	$16.06B	$3.55
NVS Novartis Ag Adr	$304.99B	$54.66B	$13.58B	$16.05B	$7.02

Gilead Sciences Inc Aktie (GILD) Hochstufungen & Herabstufungen

Datum	Aktion	Analytiker	Ratingänderung
2026-07-21	Herabstufung	Leerink Partners	Outperform → Market Perform
2026-07-06	Hochstufung	HSBC Securities	Hold → Buy
2026-05-20	Hochstufung	Maxim Group	Hold → Buy
2026-03-10	Eingeleitet	Jefferies	Buy
2026-02-20	Eingeleitet	Barclays	Equal Weight
2026-02-11	Bestätigt	Needham	Buy
2026-01-07	Resumed	UBS	Buy
2025-11-24	Resumed	Truist	Buy
2025-11-13	Eingeleitet	Scotiabank	Sector Outperform
2025-08-19	Hochstufung	Daiwa Securities	Neutral → Outperform
2025-08-08	Hochstufung	Truist	Hold → Buy
2025-07-25	Hochstufung	Needham	Hold → Buy
2025-04-22	Resumed	Cantor Fitzgerald	Overweight
2025-03-04	Bestätigt	Oppenheimer	Outperform
2025-02-18	Hochstufung	Deutsche Bank	Hold → Buy
2025-02-13	Hochstufung	DZ Bank	Hold → Buy
2025-01-10	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2024-12-10	Resumed	BofA Securities	Buy
2024-11-15	Eingeleitet	Wolfe Research	Outperform
2024-11-14	Eingeleitet	Citigroup	Buy
2024-11-08	Herabstufung	Maxim Group	Buy → Hold
2024-10-21	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-10-17	Eingeleitet	Bernstein	Outperform
2024-10-07	Hochstufung	Wells Fargo	Equal Weight → Overweight
2024-07-08	Hochstufung	Raymond James	Mkt Perform → Outperform
2024-05-01	Bestätigt	Maxim Group	Buy
2024-04-24	Hochstufung	HSBC Securities	Reduce → Hold
2024-02-22	Herabstufung	Truist	Buy → Hold
2023-11-09	Eingeleitet	Deutsche Bank	Hold
2023-09-08	Hochstufung	BofA Securities	Neutral → Buy
2023-09-06	Eingeleitet	HSBC Securities	Reduce
2023-07-24	Bestätigt	Barclays	Equal Weight
2023-05-16	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2023-04-28	Resumed	Piper Sandler	Overweight
2023-01-03	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2022-12-13	Resumed	BofA Securities	Neutral
2022-12-09	Herabstufung	DZ Bank	Buy → Hold
2022-10-31	Hochstufung	Barclays	Underweight → Equal Weight
2022-10-28	Bestätigt	BMO Capital Markets	Market Perform
2022-10-28	Bestätigt	Cowen	Outperform
2022-10-28	Bestätigt	JP Morgan	Overweight
2022-10-28	Bestätigt	Jefferies	Buy
2022-10-28	Hochstufung	Piper Sandler	Neutral → Overweight
2022-10-28	Bestätigt	RBC Capital Mkts	Outperform
2022-10-28	Hochstufung	Truist	Hold → Buy
2022-10-28	Bestätigt	Wells Fargo	Equal Weight
2022-10-04	Hochstufung	JP Morgan	Neutral → Overweight
2022-07-13	Eingeleitet	Cantor Fitzgerald	Neutral
2022-05-23	Eingeleitet	SVB Leerink	Mkt Perform
2022-02-28	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2022-02-02	Bestätigt	BMO Capital Markets	Outperform
2022-02-02	Bestätigt	BofA Securities	Neutral
2022-02-02	Bestätigt	RBC Capital Mkts	Outperform
2022-02-02	Bestätigt	Truist	Hold
2022-02-02	Bestätigt	Wells Fargo	Equal Weight
2022-01-28	Hochstufung	Argus	Hold → Buy
2022-01-06	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-12-09	Resumed	Wells Fargo	Equal Weight
2021-12-06	Eingeleitet	Goldman	Neutral
2021-11-19	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2021-11-19	Resumed	Piper Sandler	Neutral
2021-10-20	Resumed	Cowen	Outperform
2021-07-30	Bestätigt	BMO Capital Markets	Market Perform
2021-07-30	Bestätigt	RBC Capital Mkts	Outperform
2021-04-01	Hochstufung	Bernstein	Mkt Perform → Outperform
2021-03-30	Hochstufung	Redburn	Neutral → Buy
2021-01-19	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2021-01-04	Hochstufung	Guggenheim	Neutral → Buy
2020-11-03	Resumed	Morgan Stanley	Equal-Weight
2020-10-28	Eingeleitet	UBS	Neutral
2020-09-30	Resumed	Jefferies	Buy
2020-09-15	Hochstufung	Maxim Group	Hold → Buy
2020-07-31	Bestätigt	Credit Suisse	Neutral
2020-07-31	Bestätigt	Morgan Stanley	Equal-Weight
2020-07-31	Bestätigt	Piper Sandler	Overweight
2020-07-31	Bestätigt	RBC Capital Mkts	Outperform
2020-07-31	Bestätigt	SunTrust	Hold
2020-07-31	Bestätigt	Wells Fargo	Equal Weight
2020-07-20	Hochstufung	Credit Suisse	Underperform → Neutral
2020-06-03	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2020-05-26	Hochstufung	SunTrust	Sell → Hold
2020-05-01	Herabstufung	JP Morgan	Overweight → Neutral
2020-05-01	Herabstufung	Raymond James	Outperform → Mkt Perform
2020-05-01	Herabstufung	SunTrust	Hold → Sell
2020-04-27	Herabstufung	UBS	Buy → Neutral
2020-04-20	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2020-04-20	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-04-17	Herabstufung	CFRA	Hold → Sell

Finanzdaten der Gilead Sciences Inc-Aktie (GILD)

Zeitraum	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Enddatum des Zeitraums	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	29,443.00	28,754.00	27,116.00	27,281.00	27,305.00
Cost of revenue USD (M)	6,234.00	6,251.00	6,498.00	5,657.00	6,601.00
Gross profit USD (M)	-	-	20,618.00	21,624.00	20,704.00
Operating expenses USD (M)	19,421.00	27,092.00	13,013.00	14,294.00	10,786.00
Operating income USD (M)	10,022.00	1,662.00	7,605.00	7,330.00	9,918.00
Income before tax USD (M)	9,796.00	690.00	6,859.00	5,814.00	8,278.00
Income tax expense USD (M)	1,286.00	211.00	1,247.00	1,248.00	2,077.00
Net income USD (M)	8,510.00	480.00	5,613.00	4,566.00	6,201.00
Basic EPS USD/shares	6.84	0.38	4.54	3.66	4.96
Diluted EPS USD/shares	6.78	0.38	4.50	3.64	4.93
Basic weighted shares shares (M)	1,244.00	1,247.00	1,248.00	1,255.00	1,256.00
Diluted weighted shares shares (M)	1,255.00	1,255.00	1,258.00	1,262.00	1,262.00
Selling, general and administrative USD (M)	5,774.00	6,091.00	6,090.00	5,673.00	5,246.00

Gilead Sciences Inc-Aktie (GILD) Insiderhandel

DANIEL O'DAYOct 30 '26
Director
Transaktion
Proposed Sale
Kosten
$165.61
#Aktien
45,881
Wert ($)
7,598,352
#Aktien Gesamt
0
Mercier JohannaOct 15 '26
Chief Comm & Corp Aff Officer
Transaktion
Sale
Kosten
$156.22
#Aktien
3,000
Wert ($)
468,660
#Aktien Gesamt
113,684
JOHANNA MERCIEROct 15 '26
Officer
Transaktion
Proposed Sale
Kosten
$156.22
#Aktien
3,000
Wert ($)
468,660
#Aktien Gesamt
0
Dickinson Andrew DOct 15 '26
Chief Financial Officer
Transaktion
Sale
Kosten
$156.22
#Aktien
3,000
Wert ($)
468,660
#Aktien Gesamt
161,096
ANDREW DICKINSONOct 15 '26
Officer
Transaktion
Proposed Sale
Kosten
$156.22
#Aktien
3,000
Wert ($)
468,660
#Aktien Gesamt
0
O'Day Daniel PatrickOct 01 '26
Chairman & CEO
Transaktion
Sale
Kosten
$147.90
#Aktien
15,000
Wert ($)
2,218,508
#Aktien Gesamt
566,683
ANDREW DICKINSONSep 15 '26
Officer
Transaktion
Proposed Sale
Kosten
$145.29
#Aktien
3,000
Wert ($)
435,870
#Aktien Gesamt
0
Mercier JohannaSep 15 '26
Chief Comm & Corp Aff Officer
Transaktion
Sale
Kosten
$144.22
#Aktien
3,000
Wert ($)
432,646
#Aktien Gesamt
116,684
Dickinson Andrew DSep 15 '26
Chief Financial Officer
Transaktion
Sale
Kosten
$145.29
#Aktien
3,000
Wert ($)
435,870
#Aktien Gesamt
164,096
JOHANNA MERCIERSep 15 '26
Officer
Transaktion
Proposed Sale
Kosten
$144.22
#Aktien
3,000
Wert ($)
432,646
#Aktien Gesamt
0

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
DANIEL O'DAY	Director	Oct 30 '26	Proposed Sale	$165.61	45,881	7,598,352	0
Mercier Johanna	Chief Comm & Corp Aff Officer	Oct 15 '26	Sale	$156.22	3,000	468,660	113,684
JOHANNA MERCIER	Officer	Oct 15 '26	Proposed Sale	$156.22	3,000	468,660	0
Dickinson Andrew D	Chief Financial Officer	Oct 15 '26	Sale	$156.22	3,000	468,660	161,096
ANDREW DICKINSON	Officer	Oct 15 '26	Proposed Sale	$156.22	3,000	468,660	0
O'Day Daniel Patrick	Chairman & CEO	Oct 01 '26	Sale	$147.90	15,000	2,218,508	566,683
ANDREW DICKINSON	Officer	Sep 15 '26	Proposed Sale	$145.29	3,000	435,870	0
Mercier Johanna	Chief Comm & Corp Aff Officer	Sep 15 '26	Sale	$144.22	3,000	432,646	116,684
Dickinson Andrew D	Chief Financial Officer	Sep 15 '26	Sale	$145.29	3,000	435,870	164,096
JOHANNA MERCIER	Officer	Sep 15 '26	Proposed Sale	$144.22	3,000	432,646	0

Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten

Nov 02, 2026

Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today - Benzinga

Nov 02, 2026

Bernstein raises Gilead Sciences stock price target on strong growth - Investing.com

Nov 02, 2026

Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow - Yahoo Finance

Nov 02, 2026